Status:

SUSPENDED

Matching Donor Human Milk On Maternal Secretor Status (MMOMSS) Study

Lead Sponsor:

University of Manitoba

Collaborating Sponsors:

University of Calgary

Conditions:

Microbial Colonization

Preterm Birth

Eligibility:

All Genders

18+ years

Phase:

NA

Brief Summary

This study will evaluate the impact of matching donor human milk to the maternal secretor status of very preterm infants (\<34 weeks gestation) on the gut microbiome. Half of enrolled infants will rec...

Detailed Description

Background: The gut microbiome is established early in life and plays an important role in developing the immune system and metabolism. Infants born prematurely (before 37-weeks gestation) account for...

Eligibility Criteria

Inclusion

  • Inclusion Criteria:
  • Gestation up to 33 6/7 weeks at hospital admission (to guarantee at least 14 days intervention, since DHM fortification typically ends at 34+0 weeks adjusted gestational age).
  • Provision of consent for infant to receive DHM.
  • Mother has provided signed and dated informed consent and authorization to use protected health information, as required by national and local regulations.
  • In the investigator's opinion, the subject mother understands and is able to comply with protocol requirements, instructions, and protocol-stated restrictions, and is likely to complete the study as planned.
  • Exclusion Criteria (Infant):
  • Diagnosed with clinically significant major congenital malformation
  • Intestinal perforation or stage 2 necrotizing enterocolitis (NEC)
  • Unlikely to survive the study period
  • Receiving extended courses of antibiotics (most infants are expected to receive up to 48hr antibiotic prophylaxis at birth according to standard NICU protocol; this criterion will only exclude infants receiving prolonged courses of antibiotics)
  • Presence prior to enrollment of intestinal perforation or stage 2 necrotizing enterocolitis (NEC) prior to tolerating fortified feeds

Exclusion

    Key Trial Info

    Start Date :

    May 29 2023

    Trial Type :

    INTERVENTIONAL

    Allocation :

    ESTIMATED

    End Date :

    December 31 2025

    Estimated Enrollment :

    60 Patients enrolled

    Trial Details

    Trial ID

    NCT04130165

    Start Date

    May 29 2023

    End Date

    December 31 2025

    Last Update

    December 6 2024

    Active Locations (1)

    Enter a location and click search to find clinical trials sorted by distance.

    Page 1 of 1 (1 locations)

    1

    University of Calgary

    Calgary, Alberta, Canada